Journal of Cancer Research and Therapeutics Close
 

Figure 2: High long noncoding RNA activated by transforming growth factor-β expression correlates with poor OS and PFS of cervical cancer patients and subgroup patients. (a and b) Log-rank test was adopted to investigate the OS (a) and PFS (b) differences between the activated by transforming growth factor-β low expression group and the activated by transforming growth factor-β high expression group of cervical cancer patients. (c-f) The OS differences between the activated by transforming growth factor-β low expression group and the activated by transforming growth factor-β high expression group in the cervical cancer patients without lymph node metastasis (c), with lymph node metastasis (d), with International Federation of Gynecology and Obstetrics Stage I (e), and with International Federation of Gynecology and Obstetrics Stage II (f) were analyzed. P < 0.05 based on log-rank test. OS = Overall survival, PFS = Progression-free survival

Figure 2: High long noncoding RNA activated by transforming growth factor-β expression correlates with poor OS and PFS of cervical cancer patients and subgroup patients. (a and b) Log-rank test was adopted to investigate the OS (a) and PFS (b) differences between the activated by transforming growth factor-β low expression group and the activated by transforming growth factor-β high expression group of cervical cancer patients. (c-f) The OS differences between the activated by transforming growth factor-β low expression group and the activated by transforming growth factor-β high expression group in the cervical cancer patients without lymph node metastasis (c), with lymph node metastasis (d), with International Federation of Gynecology and Obstetrics Stage I (e), and with International Federation of Gynecology and Obstetrics Stage II (f) were analyzed. <i>P</i> < 0.05 based on log-rank test. OS = Overall survival, PFS = Progression-free survival